Christopher Wallis, MD, PhD, FRCSC

Christopher Wallis, MD, PhD, FRCSC
Assistant Professor, Division of Urology, University of Toronto
Urologic Oncologist, Division of Urology, Mount Sinai Hospital and University Health Network

Articles by Christopher Wallis, MD, PhD, FRCSC

Sia Daneshmand, MDASCO GU Symposium 2024 | February 6, 2024
Drs. Daneshmand and Wallis highlight two trials in progress in NMIBC: ABLE-41 and PIVOT-006.
View More
Christopher Wallis, MD, PhD, FRCSCASCO GU Symposium 2024 | February 5, 2024
In patients with high-risk resected UC, adjuvant pembro is associated with improvement in disease-free survival.
Christopher Wallis, MD, PhD, FRCSCASCO GU Symposium 2024 | January 30, 2024
Dr. Wallis highlights his population-based research on treatment intensification shortcomings in de novo mCSPC.
Pedro Barata, MDASCO GU Symposium 2024 | January 30, 2024
Drs. Barata and Wallis highlight the efficacy of pem/len and how this IO/TKI approach compares to other strategies for aRCC.
Pedro Barata, MDASCO GU Symposium 2024 | January 30, 2024
Drs. Barata and Wallis discuss the interaction of age and benefit of treatment intensification in advanced prostate cancer.
Brad McGregor, MDASCO GU Symposium 2024 | January 26, 2024
Drs. McGregor and Wallis continue their discussion by pivoting to the BLASST-1 trial.
Brad McGregor, MDASCO GU Symposium 2024 | January 30, 2024
Drs. McGregor and Wallis highlight CONTACT-2, the first study of an ICI-based regimen to show improvement in rPFS in PC.
Karen Hoffman, MD, MHSc, MPHASCO GU Symposium 2024 | January 30, 2024
Drs. Hoffman and Wallis discuss the HRQoL from FORMULA-509 trial, showing no difference in hormonal function and fatigue.
Christopher Wallis, MD, PhD, FRCSCASCO GU Symposium 2024 | January 25, 2024
Dr. Maha Hussain presented results of the BRCAAway trial in patients with mCRPC who have HRR mutations.
Ariana L. Smith, MDSUO 2023 | December 20, 2023
Drs. Smith and Wallis shed light on how urologists can reduce risks and improve the well-being of their female patients.
Stephen J. Freedland, MDLocalized | December 12, 2023
Drs. Freedland and Wallis continue their EMBARK discussions and recommendations for treating high-risk BCR prostate cancer.
Stephen J. Freedland, MDLocalized | December 12, 2023
Drs. Freedland and Wallis discuss the details of the NEJM phase 3 EMBARK study on enzalutamide in BCR prostate cancer.
Christopher Wallis, MD, PhD, FRCSCRoundtable | December 8, 2023
The panel conclude with their thoughts on considerations for TURBT and intravesical therapy versus chemoablation.
Christopher Wallis, MD, PhD, FRCSCRoundtable | December 8, 2023
The panel considers therapies across different risk stratifications, including ATLAS, ENVISION, and BOND-003 studies.
Christopher Wallis, MD, PhD, FRCSCRoundtable | December 8, 2023
The panel delves into treatment pathways, including considerations for ablation and repeated histologic evaluation.
Christopher Wallis, MD, PhD, FRCSCRoundtable | December 8, 2023
The panel kicked off with conversations about risk stratification and classification of low-grade, intermediate-risk disease.
Oliver Sartor, MDRLT | December 4, 2023
Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | December 18, 2023
Drs. Joyce and Wallis consider the impact of financial toxicity and containing costs for patients with GU malignancies.
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | December 18, 2023
Drs. Pal and Wallis break down the role of the microbiome and response in patients with kidney cancer.
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | November 30, 2023
Dr. Prasad presented the results of the ENVISION trial assessing primary chemoablation in patients with LG-IR NMIBC.